A clinical trial of IMP-7068 in China
Latest Information Update: 14 Jul 2021
At a glance
- Drugs IMP 7068 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 14 Jul 2021 New trial record
- 10 Jun 2021 According to an IMPACT Therapeutics media release, company received approval from the PRC National Medical Products Administration (NMPA) to begin this trial.